Press Releases Detail:
Carl M. Good Returns to Avitar as Vice President of Research and Development
June 06, 2002
CANTON, Mass., June 6 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: - ) today announced that Carl M. Good, Ph.D., has rejoined Avitar as Vice President of Research and Development, a position he held from 1997 until 2001, when he left for personal reasons. In his role at Avitar, Dr. Good will be responsible for leading and managing the Company's research and development efforts for ORALscreen(TM), the Company's oral fluid drugs of abuse test, as well as the development of point-of-care oral fluid diagnostics for influenza, diabetes, and other diagnostic applications.
Dr. Good brings to Avitar more than 30 years of experience in the medical diagnostics industry, especially in the design and manufacturing of rapid diagnostic tests. He has held numerous senior level positions including Vice President of Diagnostic Research and Development for Millipore Corporation, Director of Product Development for Cambridge Biotech Corporation, and President of Integrated Chemical Sensors Corporation, a company he founded.
"We are very pleased that Dr. Good has agreed to return to Avitar," said Peter P. Phildius, Avitar's Chairman and Chief Executive Officer. Mr. Phildius added, "He was responsible for the development of ORALscreen, and we look forward to accelerating the development of our products under his leadership."
In commenting on his appointment, Dr. Good said, "I am thrilled to be rejoining Avitar at this juncture and I am impressed with the progress the Company has made in my absence." He noted, "ORALscreen is quickly gaining market acceptance in the forensic and pre-employment sectors and I am eager to develop this technology for wider use in the marketplace. The point-of-care diagnostic market is enormous, and I am looking forward to bringing rapid, non-invasive testing to broader markets."
Avitar, Inc. develops, manufactures and markets innovative and proprietary products in the oral fluid diagnostic market, and the disease and clinical testing market. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of-abuse testing market, which encompasses the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, and HAIRscreen(TM), a laboratory-based hair test for detecting long-term drug abuse. In the estimated $25 billion In-Vitro diagnostics market, Avitar is developing diagnostic strategies for disease and clinical testing. Some examples include influenza, diabetes and pregnancy. For more information, see Avitar's website at avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Lippert/Heilshorn and Associates